Merck MRK announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion recommending approval of an expanded indication for its pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept). The CHMP has now recommended the approval of an expanded indication for Winrevair in combination with other PAH therapies, for the treatment of PAH in adult patients with WHO…